These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

640 related items for PubMed ID: 20836004

  • 1. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY, Li GD, Liu WP, Xie B, Jiang YH.
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [Abstract] [Full Text] [Related]

  • 2. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
    Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H.
    Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
    [Abstract] [Full Text] [Related]

  • 3. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindán J.
    Cancer; 2001 Feb 25; 93(1):68-72. PubMed ID: 11241268
    [Abstract] [Full Text] [Related]

  • 4. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
    Su XY, Li GD, Liu HB, Jiang LL.
    Ai Zheng; 2004 Oct 25; 23(10):1185-9. PubMed ID: 15473932
    [Abstract] [Full Text] [Related]

  • 5. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT, Gentile P, Tarectecan A, Fuchs A.
    Arch Pathol Lab Med; 1996 Oct 25; 120(10):959-66. PubMed ID: 12046609
    [Abstract] [Full Text] [Related]

  • 6. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
    Ueda J, Iwata T, Ono M, Takahashi M.
    Diagn Cytopathol; 2006 Jan 25; 34(1):6-10. PubMed ID: 16355377
    [Abstract] [Full Text] [Related]

  • 7. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
    Hyun TS, Barnes M, Tabatabai ZL.
    Acta Cytol; 2012 Jan 25; 56(5):527-32. PubMed ID: 23075894
    [Abstract] [Full Text] [Related]

  • 8. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
    Afify AM, Stern R, Michael CW.
    Diagn Cytopathol; 2005 Mar 25; 32(3):145-50. PubMed ID: 15690337
    [Abstract] [Full Text] [Related]

  • 9. Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: the utility of immunocytochemical panel in the differential diagnosis.
    Saleh HA, El-Fakharany M, Makki H, Kadhim A, Masood S.
    Diagn Cytopathol; 2009 May 25; 37(5):324-32. PubMed ID: 19191294
    [Abstract] [Full Text] [Related]

  • 10. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE, Novelli L, Boddi V, Paglierani M, Dini S.
    Hum Pathol; 2001 May 25; 32(5):529-36. PubMed ID: 11381372
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K.
    Pneumonol Alergol Pol; 2007 May 25; 75(1):57-69. PubMed ID: 17541913
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
    Khurram N, Anis T, Yusuf NW.
    J Coll Physicians Surg Pak; 2019 Jan 25; 29(1):33-36. PubMed ID: 30630566
    [Abstract] [Full Text] [Related]

  • 16. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
    Dejmek A, Hjerpe A.
    Diagn Cytopathol; 2005 Mar 25; 32(3):160-6. PubMed ID: 15690331
    [Abstract] [Full Text] [Related]

  • 17. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
    Shield PW, Koivurinne K.
    Cytopathology; 2008 Aug 25; 19(4):218-23. PubMed ID: 17916095
    [Abstract] [Full Text] [Related]

  • 18. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M, Hoogsteden HC, Van der Kwast TH.
    J Pathol; 1991 Oct 25; 165(2):137-43. PubMed ID: 1744800
    [Abstract] [Full Text] [Related]

  • 19. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
    Li XJ, Pan QJ, Shen GH, Liu XY, Sun YT.
    Zhonghua Zhong Liu Za Zhi; 2005 Jul 25; 27(7):438-41. PubMed ID: 16188134
    [Abstract] [Full Text] [Related]

  • 20. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR, Zhai J.
    Diagn Cytopathol; 2005 Mar 25; 32(3):137-44. PubMed ID: 15690333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.